[go: up one dir, main page]

WO2005001022A3 - Methods and compositions for enhancing immune response - Google Patents

Methods and compositions for enhancing immune response Download PDF

Info

Publication number
WO2005001022A3
WO2005001022A3 PCT/US2004/011085 US2004011085W WO2005001022A3 WO 2005001022 A3 WO2005001022 A3 WO 2005001022A3 US 2004011085 W US2004011085 W US 2004011085W WO 2005001022 A3 WO2005001022 A3 WO 2005001022A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
immune response
enhancing immune
irm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/011085
Other languages
French (fr)
Other versions
WO2005001022A2 (en
Inventor
Richard L Miller
Mark A Tomai
Ross M Kedl
Isidro Angelo E Zarraga
Ronnie Ortiz
James D Stoesz
Paul D Wightman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Innovative Properties Co
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/640,904 external-priority patent/US7427629B2/en
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Priority to CA002521662A priority Critical patent/CA2521662A1/en
Priority to EP04775877A priority patent/EP1617872A4/en
Priority to AU2004252409A priority patent/AU2004252409A1/en
Priority to JP2006532393A priority patent/JP2007514644A/en
Publication of WO2005001022A2 publication Critical patent/WO2005001022A2/en
Publication of WO2005001022A3 publication Critical patent/WO2005001022A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.
PCT/US2004/011085 2003-04-10 2004-04-09 Methods and compositions for enhancing immune response Ceased WO2005001022A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002521662A CA2521662A1 (en) 2003-04-10 2004-04-09 Methods and compositions for enhancing immune response
EP04775877A EP1617872A4 (en) 2003-04-10 2004-04-09 Methods and compositions for enhancing immune response
AU2004252409A AU2004252409A1 (en) 2003-04-10 2004-04-09 Methods and compositions for enhancing immune response
JP2006532393A JP2007514644A (en) 2003-04-10 2004-04-09 Methods and compositions for improving immune response

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US46214003P 2003-04-10 2003-04-10
US60/462,140 2003-04-10
US10/640,904 2003-08-14
US10/640,904 US7427629B2 (en) 2002-08-15 2003-08-14 Immunostimulatory compositions and methods of stimulating an immune response
US51525603P 2003-10-29 2003-10-29
US60/515,256 2003-10-29
US53370303P 2003-12-31 2003-12-31
US60/533,703 2003-12-31
US54554204P 2004-02-18 2004-02-18
US54542404P 2004-02-18 2004-02-18
US60/545,424 2004-02-18
US60/545,542 2004-02-18

Publications (2)

Publication Number Publication Date
WO2005001022A2 WO2005001022A2 (en) 2005-01-06
WO2005001022A3 true WO2005001022A3 (en) 2005-09-15

Family

ID=34923557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011085 Ceased WO2005001022A2 (en) 2003-04-10 2004-04-09 Methods and compositions for enhancing immune response

Country Status (5)

Country Link
EP (1) EP1617872A4 (en)
JP (1) JP2007514644A (en)
AU (1) AU2004252409A1 (en)
CA (1) CA2521662A1 (en)
WO (1) WO2005001022A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314535B2 (en) 2009-09-03 2016-04-19 Curevac Ag Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US9572874B2 (en) 2008-09-30 2017-02-21 Curevac Ag Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006007433A1 (en) * 2006-02-17 2007-08-23 Curevac Gmbh Adjuvant in the form of a lipid-modified nucleic acid
JP2010507361A (en) 2006-07-31 2010-03-11 キュアバック ゲーエムベーハー Specifically, a nucleic acid represented by the general formula (I): GlXmGn or the general formula (II): ClXmCn, as an immunostimulant/adjuvant.
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
MX2010008468A (en) 2008-01-31 2010-08-30 Curevac Gmbh NUCLEIC ACIDS COMPRISING FORMULA (NuGlX<sub >mGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS.
KR20110077004A (en) 2008-10-24 2011-07-06 글락소스미스클라인 바이오로지칼즈 에스.에이. Lipidated Imidazoquinoline Derivatives
CA2801523C (en) 2010-07-30 2021-08-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
ES2747762T3 (en) 2013-08-21 2020-03-11 Curevac Ag Respiratory syncytial virus (RSV) vaccine
CR20160214A (en) * 2013-11-05 2016-10-11 3M Innovative Properties Co INJECTION FORMULATIONS BASED ON SESAME OIL
WO2015149944A2 (en) 2014-04-01 2015-10-08 Curevac Gmbh Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
EP3355933B1 (en) 2015-09-29 2020-05-06 Sumitomo Dainippon Pharma Co., Ltd. Adenine conjugate compounds and their use as vaccine adjuvants
CN108290845B (en) 2015-10-07 2021-08-03 大日本住友制药株式会社 Pyrimidine compounds
MA44334A (en) 2015-10-29 2018-09-05 Novartis Ag ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
IL263616B2 (en) 2016-07-07 2025-01-01 Univ Leland Stanford Junior Antibody adjuvant conjugates
MX2021000951A (en) 2018-07-23 2021-06-23 Sumitomo Pharma Co Ltd Composition containing influenza vaccine.
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447724A (en) * 1990-05-17 1995-09-05 Harbor Medical Devices, Inc. Medical device polymer
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6486214B1 (en) * 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US6518280B2 (en) * 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194581A (en) * 1989-03-09 1993-03-16 Leong Kam W Biodegradable poly(phosphoesters)
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US6273913B1 (en) * 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
SK287112B6 (en) * 1999-01-08 2009-12-07 3M Innovative Properties Company Use of immune response modifiying compound for cervical dysplasias treatment
WO2002046749A2 (en) * 2000-12-08 2002-06-13 3M Innovative Properties Company Screening method for identifying compounds that selectively induce interferon alpha
CN1292751C (en) * 2002-04-23 2007-01-03 四川大学 Imiquimod or its derivative liposome for local skin and its preparing method and use
DK1545597T3 (en) * 2002-08-15 2011-01-31 3M Innovative Properties Co Immune Stimulating Compositions and Methods for Stimulating an Immune Response
DE60322111D1 (en) * 2002-12-31 2008-08-21 Nektar Therapeutics Al Co METHOD FOR THE PRODUCTION OF HYDROGELES FROM THIOSULFONATE COMPOSITIONS AND THEIR USES

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447724A (en) * 1990-05-17 1995-09-05 Harbor Medical Devices, Inc. Medical device polymer
US6486214B1 (en) * 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US6518280B2 (en) * 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6486168B1 (en) * 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GIBSON S.J. ET AL: "Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod", CELL IMMUNOL, vol. 218, 2002, pages 74 - 86, XP002985828 *
See also references of EP1617872A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572874B2 (en) 2008-09-30 2017-02-21 Curevac Ag Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US9314535B2 (en) 2009-09-03 2016-04-19 Curevac Ag Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids

Also Published As

Publication number Publication date
AU2004252409A1 (en) 2005-01-06
EP1617872A2 (en) 2006-01-25
WO2005001022A2 (en) 2005-01-06
CA2521662A1 (en) 2005-01-06
EP1617872A4 (en) 2011-09-07
JP2007514644A (en) 2007-06-07

Similar Documents

Publication Publication Date Title
WO2005001022A3 (en) Methods and compositions for enhancing immune response
WO2005055932A3 (en) Therapeutic combinations and methods including irm compounds
WO2006093524A3 (en) Antigen-carbohydrate conjugates
WO2004082822A3 (en) Methods for isolating crystalline form i of 5-azacytidine
WO2004080430A3 (en) Methods of improving skin quality
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
WO2006015371A3 (en) Humanized anti-cmet antagonists
WO2006023651A3 (en) Extended treatment of multiple sclerosis
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
WO2005019258A3 (en) Compositions and methods for the treatment of immune related diseases
WO2004078138A3 (en) Prophylactic treatment of uv-induced epidermal neoplasia
WO2004024068A3 (en) Novel composition and methods for the treatment of immune related diseases
WO2006130399A3 (en) Therapeutic combinations and methods including irm compounds
WO2005021497A3 (en) Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
WO2005009928A3 (en) Preparation and use of alkylating agents
WO2004087073A3 (en) Treatment of demyelinating conditions
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
EP1344515A4 (en) Skin cosmetics
WO2004024076A8 (en) Novel compositions and methods for the treatment of immune related diseases
WO2009057954A3 (en) Composition for improvement of fatty liver
AU2003212344A1 (en) Use of extracts from olive trees as anti-dandruff agents
AU2003212936A1 (en) Peptide-dependent upregulation of telomerase expression
WO2004100873A3 (en) Compounds, compositions, and methods
WO2005005382A3 (en) Compounds, compositions and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2521662

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004252409

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006532393

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004252409

Country of ref document: AU

Date of ref document: 20040409

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004252409

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004775877

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004775877

Country of ref document: EP